Home » Newsletters » BioWorld Science

BioWorld Science

Nov. 6, 2020

View Archived Issues

Three-for-two method predicts immune response

Saillant obtains preclinical proof of concept with ST-02 for heart failure

European Commission approves Forxiga for HFrEF

First patient with AML dosed in phase I/II study of RTX-240

Hinova Pharmaceuticals describes PROTAC androgen receptor degraders

CLR-131 shows preliminary activity in pediatric brain and solid tumors

New anti-PD-L1 antibodies patented by Scripps Korea Antibody Institute

Bioardis discovers CD73 inhibitors

Dizal (Jiangsu) Pharmaceutical presents new JAK1 inhibitors

[64Cu]PSMA I&T shows promise for PSMA-specific PET imaging

Medshine Discovery synthesizes new factor XIa inhibitors

Active pipeline of potential new lupus therapies unfolding as ACR begins

New study to evaluate CymaBay's MBX-2982 for hypoglycemia in type 1 diabetes

Oral mucositis treatment GC-4419 does not affect tumor control outcomes in phase II trial

Acurx reports phase IIa data on ibezapolstat in C. difficile infection

SYNB-8802 consumes GI oxalate in animals with acute hyperoxaluria

Preclinical data on EBS-LASV vaccine presented

[18F]AS3504073-00: a PET tracer for imaging mitochondrial fatty acid beta-oxidation in the heart

Phase I data presented for iCo-019, novel oral formulation of amphotericin B

Genmab to conduct phase III study of epcoritamab in DLBCL

Puma reports interim phase II data on neratinib in EGFR exon 18 mutated metastatic NSCLC

Phase II extension study of vebicorvir in HBV does not achieve meaningful SVR rates

Scientists identify distinct type of membranous nephropathy linked to protocadherin 7

CAN-COVID trial of canakinumab in patients with COVID-19 pneumonia and CRS misses endpoints

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for July 31, 2026.
Tuojie Biotech (Shanghai) synthesizes new SARM1 inhibitors
BioWorld Science
Tuojie Biotech (Shanghai) Co. Ltd. has prepared and tested NAD(+) hydrolase SARM1 (SAMD2; MyD88-5) inhibitors found to be potentially useful for the treatment of...
Death in Chinese gene-editing trial exposes ethical fault lines
BioWorld
The death of a 6-year-old girl after receiving an experimental brain-directed gene-editing therapy at the Xinhua Hospital in Shanghai has reopened debate over how...
Seed funding at Adjuvia to treat mitochondrial dysfunction
BioWorld Science
Adjuvia Therapeutics Inc. has closed a $8 million series seed financing round to advance its work developing therapeutics to treat mitochondrial dysfunction and...
Replimune’s RP-1 for melanoma wins over FDA adcom
BioWorld
Following two complete response letters in the past year, Replimune Group Inc.’s RP-1 (suvolimogene oderparepvec) for unresectable metastatic cutaneous melanoma...